Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
نویسندگان
چکیده
منابع مشابه
Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer.
OBJECTIVES In clinical trials of new cancer drugs, reliable data for progression-free survival will often become available far sooner than reliable data for overall survival. The aim of this study was to determine how many months it would be expected that any given new drug for metastatic breast or colorectal cancer will add to overall survival times given that the number of months the drug add...
متن کاملChromothripsis and progression-free survival in metastatic colorectal cancer
Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromot...
متن کاملPrognostic factors for progression-free and overall survival in advanced biliary tract cancer.
BACKGROUND Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease. METHODS Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously i...
متن کاملInterval or Late Debulking Surgery in Advanced Ovarian Cancer: Progression Free and Overall Survival Advantages
Purpose: Interval (IDS) or late debulking surgery (LDS) following neoadjuvant chemotherapy (NAC) may have a role in treating advanced epithelial ovarian cancer (AEOC) where primary debulking surgery is not possible. We aimed to study the outcome of such patients who were treated in our centre during the last 3 years. Methods: This was retrospective study of AEOC patients who had NAC with or wit...
متن کاملOverall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuva...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2013
ISSN: 0923-7534
DOI: 10.1093/annonc/mds289